Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy.
about
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein bindingCancer, inflammation and the AT1 and AT2 receptorsCoordinating Role of RXRα in Downregulating Hepatic Detoxification during Inflammation Revealed by Fuzzy-Logic ModelingRegulation of MRP2/ABCC2 and BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-{alpha}, IL-6, and IL-1{beta}Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO.Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.Intertissue flow of glutathione (GSH) as a tumor growth-promoting mechanism: interleukin 6 induces GSH release from hepatocytes in metastatic B16 melanoma-bearing mice.Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism.Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinomaClinical pharmacology of chemotherapy agents in older people with cancerRefractory cachexia is associated with increased plasma concentrations of fentanyl in cancer patientsPharmacokinetic variability of anticancer agents.Proposal for a recovery prediction method for patients affected by acute mediastinitis.Regulation of drug metabolism and disposition during inflammation and infection.Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies.The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer.Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancerThe systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer.Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations.Drug metabolism by tumours: its nature, relevance and therapeutic implications.A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancerEvaluation of recovery in iatrogenic evoked acute mediatinitisElevated pre-treatment levels of high sensitivity C-reactive protein as a potential prognosticator in patients with colorectal cancer.Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines.Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients.Therapeutic drug monitoring in cancer chemotherapy.Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response.Nuclear receptors in the cross-talk of drug metabolism and inflammation.Interaction of local anesthetics with biomembranes consisting of phospholipids and cholesterol: mechanistic and clinical implications for anesthetic and cardiotoxic effects.Systematic review of prostate cancer risk and association with consumption of fish and fish-oils: analysis of 495,321 participants.Regulation of drug transporter expression and function in the placenta.Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome.Inflammation and pharmacokinetics: potential implications for HIV-infection.Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics.Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol.CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease.Effect of Disease-Related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats.Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?
P2860
Q24602935-077B01CB-24EC-4CBE-ACA2-C1AFB16CAF0FQ24806378-58EABEA1-344C-423C-BA5B-B6A53A073461Q28551973-C830E97C-E957-41CB-BEC2-B40AB98C36CEQ28578667-D27839E3-C073-4FFB-B7B1-E0A846C093B9Q33384548-55812675-45B8-4716-844E-006467D97BDCQ34204238-A4B33091-41E0-4D52-B618-5E26456E71AFQ34962993-D5430D75-509C-4B6B-A6C9-DD5571C31412Q34987988-C832D0A6-B26E-4E9D-B810-69A1D19A4635Q35115559-9A2B0DA6-A279-4FD4-AA4D-5B1DA9B20FE8Q35159253-D2C361DB-3839-4E2C-8603-C0A2910BFB38Q35605830-E14E89CA-2157-441A-8360-6AF47DB99131Q36146910-1017074F-3457-4FFA-91FE-A1FF7A9F085BQ36457470-98A45486-F7B3-4E7A-B69A-00587B6C06D5Q36544874-A433AD1F-D67E-46A1-9561-5E1FDC585D50Q36608759-F395E118-811F-4B80-922E-4BC029D63840Q36614384-489448FB-7F35-4AB2-AF9C-827AADCFEECAQ36695064-2411DDBA-1DA8-470B-9577-DFAAC8CF6AF3Q36695683-6F26B7FD-63E3-41E4-97C9-E986CD111D89Q36887922-6DC29039-A5C3-45E8-8143-137583476D30Q37008879-78370453-CDAE-4A91-B83B-F1571F7AFA29Q37170527-48DBE637-F9F6-4F9C-934F-AC6C3C0D9A9CQ37192925-2644000A-03EA-4987-93BF-11BE985A58E6Q37313233-839ED44C-3DA8-4911-8057-AD1DE8378537Q37604385-B701D18A-508F-4E92-A48B-FC222DCF8CCCQ37729245-D352DE19-45A3-45A6-A0A1-922F12E6FEACQ37810220-9DED2FB6-1E96-4C41-B3C3-337CC51D1162Q37964754-0CFECD54-72E1-41A5-B739-DA52F81E3444Q38074993-4D673939-BFEF-460C-BAF3-EFDD5085A550Q38156766-8A4D054A-468E-4B21-8262-580C644758DBQ38286298-28BBF84C-84CB-4053-A15E-D6F34379D564Q38323562-3A47ABD6-5200-4884-9BD6-9C75CB09BBCDQ38390695-2F1A2BE4-FE8D-4862-8A59-F6AB858AFE28Q38501680-BB17EC93-FE09-4DDC-84E6-90E80B70E1B4Q38736405-7B472CE4-69C9-4EA3-A2D3-35E4C842D2A2Q38740792-9148B34D-D50B-4E6C-8389-642A17F9D042Q38803038-E05ADF15-62CF-4B39-8173-32E46D71FC6BQ38809021-1D90F752-19D6-4887-9CAB-D6231F10BF01Q38903289-A9E33873-97D2-4649-BCF1-BC1419EB8C0FQ38936812-5BA73839-8F93-4F24-B54A-5D7E4248EF60Q38972539-366950DD-646F-42CF-B9F7-C5F5DBDAE505
P2860
Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Inflammatory response: an unre ...... namics of cancer chemotherapy.
@ast
Inflammatory response: an unre ...... namics of cancer chemotherapy.
@en
type
label
Inflammatory response: an unre ...... namics of cancer chemotherapy.
@ast
Inflammatory response: an unre ...... namics of cancer chemotherapy.
@en
prefLabel
Inflammatory response: an unre ...... namics of cancer chemotherapy.
@ast
Inflammatory response: an unre ...... namics of cancer chemotherapy.
@en
P2093
P1433
P1476
Inflammatory response: an unre ...... namics of cancer chemotherapy.
@en
P2093
Kellie A Slaviero
Laurent P Rivory
Stephen J Clarke
P304
P356
10.1016/S1470-2045(03)01034-9
P577
2003-04-01T00:00:00Z